In8Bio (INAB) Current Assets (2020 - 2026)
In8Bio (INAB) posted Current Assets of $22.7 million for Q1 2026, down 18.72% sequentially from $27.9 million in Q4 2025, and up 78.09% YoY from $12.7 million in Q1 2025.
In8Bio (INAB) Current Assets (2020 - 2026) Analysis & Trends
In8Bio has reported Current Assets for 7 years, with the latest figure at $22.7 million in Q1 2026.
- Quarterly Current Assets rose 78.09% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.7 million (up 78.09% YoY) and the FY2025 annual result came in at $27.9 million, up 121.66% from the prior year.
- Current Assets slipped to $22.7 million in Q1 2026 per INAB's latest filing, from $27.9 million in the prior quarter.
- Over five years, Current Assets peaked at $33.3 million in Q1 2022 and troughed at $6.7 million in Q3 2024.
- A 5-year average of $19.2 million and a median of $18.0 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets surged 121.9% in 2022, then slumped 59.5% in 2024.
- Over 5 years, Current Assets stood at $22.2 million in 2022, then grew by 10.75% to $24.6 million in 2023, then sank by 48.92% to $12.6 million in 2024, then soared by 121.66% to $27.9 million in 2025, then decreased by 18.72% to $22.7 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $22.7 million, $27.9 million, and $11.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 1.76 Bn |
| 10 | In8Bio | 23.11 Mn | 23.11 Mn | - | 18.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.50 Mn |
| Mar 31, 2026 | 22.66 Mn |
| Dec 31, 2025 | 27.88 Mn |
| Sep 30, 2025 | 11.77 Mn |
| Jun 30, 2025 | 13.74 Mn |
| Mar 31, 2025 | 12.73 Mn |
| Dec 31, 2024 | 12.58 Mn |
| Sep 30, 2024 | 6.70 Mn |
| Jun 30, 2024 | 12.68 Mn |
| Dec 31, 2023 | 24.63 Mn |
| Sep 30, 2023 | 16.55 Mn |
| Jun 30, 2023 | 19.47 Mn |
| Mar 31, 2023 | 14.40 Mn |
| Dec 31, 2022 | 22.23 Mn |
| Sep 30, 2022 | 29.65 Mn |
| Jun 30, 2022 | 27.00 Mn |
| Mar 31, 2022 | 33.27 Mn |
| Dec 31, 2021 | 38.98 Mn |
| Sep 30, 2021 | 43.88 Mn |
| Jun 30, 2021 | 12.17 Mn |